Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Artivion, Inc. AORT: This medical device and tissue ...

Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

The artificial intelligence (AI) boom has taken the stock market by storm. The S&P 500 (SNPINDEX: ^GSPC) has advanced 55% in ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

TreeFrog Therapeutics is making Cambridgeport Labs the site of its U.S. headquarters, leasing just under 13,500 square feet at the campus. The cell therapy biotech is moving to its own dedicated lab ...